JB Chemicals & Pharmaceuticals moves up on entering into Nephrology segment in India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
JB Chemicals & Pharmaceuticals is currently trading at Rs. 1459.20, up by 42.90 points or 3.03% from its previous closing of Rs. 1416.30 on the BSE.
The scrip opened at Rs. 1448.00 and has touched a high and low of Rs. 1493.00 and Rs. 1421.50 respectively. So far 18585 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,493.00 on 06-May-2021 and a 52 week low of Rs. 571.00 on 06-May-2020.
Last one week high and low of the scrip stood at Rs. 1493.00 and Rs. 1377.30 respectively. The current market cap of the company is Rs. 11288.60 crore.
The promoters holding in the company stood at 55.91%, while Institutions and Non-Institutions held 20.71% and 23.38% respectively.
JB Chemicals & Pharmaceuticals (JBCPL) has forayed into the area of Nephrology with a new dedicated division called ‘RENOVA’ which will endeavour to serve patients who are under treatment for Chronic Kidney Disease.
The new division will focus exclusively on comprehensive renal care ranging from the management of hypertension in Chronic Kidney Disease to End-stage renal disease. After successfully becoming one of the leading player in Hypertension with brands like Cilacar and Nicardia, JBCPL has now begun to also focus on patients with CKD.
JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).
